# IMblaze370 (NCT02788279)

> A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus cobimetinib; atezolizumab
- Indication: previously treated metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02788279
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Colorectal Cancer
- Interventions: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody; Cobimetinib; Regorafenib
- Enrollment: 363
- Primary outcome: Overall Survival (OS)

## Indexed commentary on IMblaze370 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=imblaze370-nct02788279

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02788279", "email": "<work email>"}; the inbox owner confirms by the emailed link.